Primary prevention of sudden cardiac death: Apart from the defibrillator, what is important in patients with myocardial infarction or heart failure?

Hellenic Journal of Cardiology

Volumn 48, Issue 2, 2007, Pages 89-93

  Kallergis, Eleftherios M ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Heart failure; Myocardial infarction; Primary prevention; Sudden cardiac death

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPRANOLOL; SPIRONOLACTONE;

DEFIBRILLATOR; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MORTALITY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; CONGESTIVE HEART FAILURE;

DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RISK FACTORS;

EID: 34548071706     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Josephson M, Wellens HJJ: Implantable defibrillators and sudden cardiac death. Circulation 2004; 109: 2685-2691.
2. American Heart Association. Heart Disease and Stroke Statistics - 2007 Update. Dallas, Texas: American Heart Association; 2007.
3. Huikuri H, Castellanos A, Myerburg P: Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-1482.
4. Moss AJ, Hall WJ, Cannom DS, et al: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940.
5. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-1890.
6. Moss AJ, Zareba W, Hall WJ, et al: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
7. Bardy GH, Lee KL, Mark DB, et al: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
8. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.
9. Kuck KH, Cappato R, Siebels J, Ruppel R: Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754.
10. Connolly SJ, Gent M, Roberts RS, et al: Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302.
11. Hohnloser SH, Kuck KH, Dorian P, et al: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488.
12. Echt DS, Liebson PR, Mitchell LB, et al: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788.
13. Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349: 675-682.
14. Julian DG, Camm AJ, Frangin G, et al: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.
15. Amiodarone Trials Meta-Analysis Investigators: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997; 350: 1417-1424.
16. Boutitie F, Boissel JP, Connolly SJ, et al: Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99: 2268-2275.
17. Kober L, Bloch Thomsen PE, Moller M, et al: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356: 2052-2058.
18. Camm AJ, Pratt CM, Schwartz PJ, et al: Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109: 990-996.
19. Lopez-Sendon J, Swedberg K, McMurray J, et al: Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 1341-1362.
20. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489-497.
21. Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E: Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 7: 1-8.
22. Olsson G, Wikstrand J, Warnold I, et al: Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992; 13: 28-32.
23. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
24. McMurray J, Kober L, Robertson M, et al: Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.
25. Brodine W, Tung R, Lee J: Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol 2005; 96: 691-695.
26. Lopez-Sendon J, Swedberg K, McMurray J, et al: Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 1454-1470.
27. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598-604.
28. Lee V, Rhew D, Dylan M, et al: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693-704.
29. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
30. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
31. Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
32. Chiu JH, Abdelhadi RH, Chung MK, et al: Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005; 95: 490-491.
33. Vyas AK, Guo H, Moss AJ, et al: MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 769-773.
34. Albert CM, Hennekens CH, O'Donnell CJ, et: al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28.
35. Marchioli R, Barzi F, Bomba E, et al: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903.